Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Aurobindo Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1122.7, up 0.22% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 25402.2. The Sensex is at 83287.99, up 0.64%. Aurobindo Pharma Ltd has slipped around 5.75% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 0.94% in last one month and is currently quoting at 21804.8, down 0.35% on the day. The volume in the stock stood at 7.57 lakh shares today, compared to the daily average of 12.2 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1121.7, up 0.22% on the day. Aurobindo Pharma Ltd is down 5.52% in last one year as compared to a 5.65% jump in NIFTY and a 11.34% jump in the Nifty Pharma index.
The PE of the stock is 37.57 based on TTM earnings ending March 25.
Titgarh Rail Systems shares are banned from F&O trading on 25 June 2025.
Stocks to Watch:
PTC Industries’ subsidiary, Aerolloy Technologies announced the memorandum of understanding (MoU) with Safran Aircraft Engines to develop cooperation on the manufacturing of components and materials for military aircraft engines.
Mastek’s chief financial officer, Raghavendra Jha has submitted his resignation from the services.
Aurobindo Pharma’s wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg.
JB Chemicals & Pharmaceuticals has received approval from United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA), Amitriptyline Hydrochloride tablets.
Rashtriya Chemicals & Fertilizers (RCF)’s board approved raising non convertible debentures (NCDs) worth Rs 300 crore on private placement basis.
Hindalco Industries has announced the acquisition of 100% equity stake in US-based AluChem Companies for an enterprise value of $125 million. The acquisition will be carried out through Aditya Holdings LLC, a stepdown wholly owned subsidiary of Hindalco.
Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a 'biosimilar medicine'; this means that Dyrupeg is highly similar to another biological medicine (the 'reference medicine’) that is already authorised in the area of the regulatory agency.
Dyrupeg is intended for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC).
This is CuraTeQ’s third biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025.
Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.
The company’s consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24.
The scrip advanced 0.84% to currently trade at Rs 1113.25 on the BSE.